Medicine today focuses largely on diagnosing existent medical conditions and remediating them, typically with surgery, drugs, chemicals, radiation, or some combination thereof.  

Why wait for a problem to happen that you know will happen?  Most people don't die of old age or one disease or condition: most people die of multiple diseases or chronic conditions stemming from or exacerbated by the confluence of common root causes: decline of immune system function, oxidative stress, and chronic inflammation.   

We know diet and exercise can help mitigate these conditions.  But even people with good diets and exercise die of diseases medicine cannot cure because they lack immune system functionality to combat the disease, and medicine or drugs often impair the body's ability to fight for itself. Jack Lalanne died of pneumonia at age 95, in nearly perfect health until a fatal moment.  He wanted to live to 120, and believed he could through good exercise and diet.  Diet and exercise matter but have limitations.  Medicine helps but makes trade offs that further weaken the body's own immune functions.

What if we could better predict predisposition for disease?  What if we could address systemic issues that form the root cause of many symptoms we call diseases?  Heart disease, cancer, Parkinson's, dementia, Alzheimer's, Rheumatoid arthritis, sclerosis -- all inextricably linked to inflammation and aging of other tissues effected by declining immune function -- could be better predicted and better prevented from developing in the first place.

We hope in our study to develop indicators to predict potential for disease states before they occur, and treatment therapies to prevent those diseases from occurring at all.  Many of the blood tests we perform have predictive potential, and we hope to extend our test suite as we accumulate data and discover patterns of commonality with rich, big data sets.
 

For many interventional studies, a randomized clinical trial takes little to no incremental effort at all: in the case of TPE, we simply gather random blood samples from people over 50 for 6 treatments, and subsequently, compare the results with subjects receiving the intervention therapy.  

Nearly 8 years worth of data and study from the AMBAR pilot and follow-on studies demonstrate beneficial effects of TPE on a majority of subjects, for example.  However, undocumented insights from medical practitioners in that study suggest other potentially beneficial effects that might provide interesting biomarkers in the future.     

Therapeutic Plasma Exchange has decades ago been approved by the U.S. F.D.A. as well as numerous international regulatory bodies; and TPE may be one of the lowest risk medical procedures available today.  We conduct clinical trials that intend to prove up (or not) beneficial effects we likely suspect to be the case, but that have not been measured and documented for our study group demographic comprehensively.   We do have data on improvements in Alzheimer's, and we have select data on accepted autoimmune conditions in older patients.  But more comprehensive measurement of systemic root causes of age-associated disorders hasn't been treated with TPE and measured comprehensively. We believe that many if not most age associated disorders have common root cause in immune system decline, oxidative stress, and chronic inflammation -- all conditions which can be addressed and improved by TPE in the application to systemic decline of aging immune systems. With supporting data, this treatment therapy might become broadly available as a medically insured prophylactic (preventive) treatment therapy for age-associated disorders.